Following a year of biological treatment with adalimumab, the concentration of pro-GN significantly increased (5.27 vs. 6.68, <i>p</i> < 0.005) in the blood of UC patients, while the level of PTX-3 decreased (3197.05 vs. 1946.4, <i>p</i> < 0.0001). The gene discussed is PTX3; the disease is ganglioneuroma.